DKCM
FDMT icon

Davidson Kempner Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Davidson Kempner Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,000
Closed -$124K – 482
2020
Q4 		$124K Buy
+3,000
New +$124K ﹤0.01% 271

Other funds holding FDMT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Davidson Kempner Capital Management's FDMT Position: Q1 2021 in Review

Davidson Kempner Capital Management sold out of 4D Molecular Therapeutics (FDMT) in Q1 2021, closing a stake of 3,000 shares — an estimated $124K sold.

Davidson Kempner Capital Management first reported a position in FDMT in Q4 2020 and held it in 1 quarter. The position peaked at $124K in Q4 2020. 64 funds tracked by Wall St. Rank hold FDMT as of Q1 2021.

  • Davidson Kempner Capital Management reported no remaining 4D Molecular Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Davidson Kempner Capital Management sold 3,000 4D Molecular Therapeutics shares in Q1 2021, an estimated $124K.
  • Davidson Kempner Capital Management first reported a position in 4D Molecular Therapeutics in Q4 2020 and held it in 1 quarter.
  • Davidson Kempner Capital Management's 4D Molecular Therapeutics position peaked at $124K in Q4 2020.
  • 64 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2021.

Based on Davidson Kempner Capital Management's 13F filing for Q1 2021, filed 17 May 2021.